ATE84973T1 - Veraenderter antikoerper. - Google Patents

Veraenderter antikoerper.

Info

Publication number
ATE84973T1
ATE84973T1 AT88907757T AT88907757T ATE84973T1 AT E84973 T1 ATE84973 T1 AT E84973T1 AT 88907757 T AT88907757 T AT 88907757T AT 88907757 T AT88907757 T AT 88907757T AT E84973 T1 ATE84973 T1 AT E84973T1
Authority
AT
Austria
Prior art keywords
pct
sec
date
altered antibodies
surface pocket
Prior art date
Application number
AT88907757T
Other languages
English (en)
Inventor
Mark William Bodmer
John Robert Adair
Nigel Richard Whittle
Alan Howard Lyons
Raymond John Owens
Original Assignee
Celltech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech Ltd filed Critical Celltech Ltd
Application granted granted Critical
Publication of ATE84973T1 publication Critical patent/ATE84973T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/801—Drug, bio-affecting and body treating compositions involving antibody or fragment thereof produced by recombinant dna technology
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT88907757T 1987-09-04 1988-09-05 Veraenderter antikoerper. ATE84973T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB878720833A GB8720833D0 (en) 1987-09-04 1987-09-04 Recombinant dna product
EP88907757A EP0348442B1 (de) 1987-09-04 1988-09-05 Veränderter antikörper
PCT/GB1988/000729 WO1989001782A1 (en) 1987-09-04 1988-09-05 Recombinant antibody

Publications (1)

Publication Number Publication Date
ATE84973T1 true ATE84973T1 (de) 1993-02-15

Family

ID=10623277

Family Applications (2)

Application Number Title Priority Date Filing Date
AT88907757T ATE84973T1 (de) 1987-09-04 1988-09-05 Veraenderter antikoerper.
AT88907749T ATE102254T1 (de) 1987-09-04 1988-09-05 Rekombinant-antikoerper.

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT88907749T ATE102254T1 (de) 1987-09-04 1988-09-05 Rekombinant-antikoerper.

Country Status (11)

Country Link
US (1) US5219996A (de)
EP (3) EP0329755A1 (de)
JP (3) JP2675380B2 (de)
AT (2) ATE84973T1 (de)
AU (3) AU614303B2 (de)
CA (2) CA1337641C (de)
DE (2) DE3888172T2 (de)
DK (3) DK172630B1 (de)
FI (3) FI892137A0 (de)
GB (1) GB8720833D0 (de)
WO (3) WO1989001974A1 (de)

Families Citing this family (228)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU625856B2 (en) * 1987-07-15 1992-07-16 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Second generation monoclonal antibodies having binding specificity to tag-72 and human carcinomas and methods for employing the same
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
JP3095168B2 (ja) * 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
KR0161525B1 (ko) * 1988-10-19 1998-12-01 리챠드 지. 워터맨 암치료를 위한 신규의 고친화성 변형된 항체군
US5215889A (en) * 1988-11-18 1993-06-01 The Regents Of The University Of California Catalytic and reactive polypeptides and methods for their preparation and use
US5162218A (en) * 1988-11-18 1992-11-10 The Regents Of The University Of California Conjugated polypeptides and methods for their preparation
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8903021D0 (en) * 1989-02-10 1989-03-30 Celltech Ltd Chemical compounds
US5354554A (en) * 1989-02-10 1994-10-11 Celltech Limited Crosslinked antibodies and processes for their preparation
GB8903022D0 (en) * 1989-02-10 1989-03-30 Celltech Ltd Chemical compounds
US5714149A (en) * 1989-02-10 1998-02-03 Celltech Therapeutics Limited Crosslinked antibodies and processes for their preparation
GB8905669D0 (en) * 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
CA2018248A1 (en) * 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
GB8916400D0 (en) * 1989-07-18 1989-09-06 Dynal As Modified igg3
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0438310A1 (de) * 1990-01-19 1991-07-24 Merck & Co. Inc. Verfahren zur Herstellung von rekombinanten Immunoglobulinen
US5185433A (en) * 1990-04-09 1993-02-09 Centocor, Inc. Cross-linking protein compositions having two or more identical binding sites
US5976531A (en) * 1990-04-19 1999-11-02 The Dow Chemical Company Composite antibodies of human subgroup IV light chain capable of binding to tag-72
US6495137B1 (en) 1990-04-19 2002-12-17 The Dow Chemical Company Humanized anti-tag-72 monoclonal antibodies using human subgroup 4 kappa light chains
GB9009549D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Recombinant antibody and method
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB2276169A (en) * 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
US5958413A (en) * 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (de) 1991-06-14 2003-11-26 Genentech, Inc. Humanisierter Heregulin Antikörper
AU654563B2 (en) * 1991-07-24 1994-11-10 Imperial Chemical Industries Plc Proteins
EP0604580A1 (de) * 1991-09-19 1994-07-06 Genentech, Inc. Expression in E.Coli von Antikörperfragmenten mit mindestens einem cystein in freier -SH Form. Anwendung in der Herstellung bifunktioneller Antikörper.
WO1993011794A1 (en) * 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
EP0618969B1 (de) * 1991-12-13 2003-06-25 The Dow Chemical Company An tag-72 bindende zusammengesetzte antikörper mit der humanen leichten kette der untergruppe-iv
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
SG49597A1 (en) 1992-02-06 1998-06-15 Schering Corp Design cloning and expression of humanized monoclonal antibodies against human interleukin-5
US6056957A (en) * 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
GB9422383D0 (en) * 1994-11-05 1995-01-04 Wellcome Found Antibodies
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US20040185039A1 (en) * 2002-08-30 2004-09-23 Heinz Kohler Therapeutic applications of noncovalent dimerizing antibodies
US20050033033A1 (en) * 1998-05-04 2005-02-10 Heinz Kohler Trans-membrane-antibody induced inhibition of apoptosis
US7569674B2 (en) * 1998-05-04 2009-08-04 Innexus Biotechnology International Limited Autophilic antibodies
US6365124B1 (en) * 1998-02-06 2002-04-02 Biocrystal, Ltd. Compositions for detecting and surgically removing lymphoid tissue involved in tumor progression
US20090208418A1 (en) * 2005-04-29 2009-08-20 Innexus Biotechnology Internaltional Ltd. Superantibody synthesis and use in detection, prevention and treatment of disease
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
CA2398466A1 (en) * 2000-01-27 2001-08-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
JP3439195B2 (ja) * 2000-02-17 2003-08-25 浜松ホトニクス株式会社 抗原の定量的検出方法
JP2003525061A (ja) 2000-03-01 2003-08-26 メディミューン，インコーポレイテッド 高効力組換え抗体およびその産生法
WO2001081401A1 (en) 2000-04-21 2001-11-01 Fuso Pharmaceutical Industries, Ltd. Novel collectins
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
EP1370589B1 (de) 2000-12-05 2006-03-15 Alexion Pharmaceuticals, Inc. Rationell entworfene antikörper
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US20020147312A1 (en) * 2001-02-02 2002-10-10 O'keefe Theresa Hybrid antibodies and uses thereof
DK1366067T3 (da) * 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
EP1532162B1 (de) 2002-06-28 2013-08-07 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Humanisierter anti-tag-72 cc49 zur diagnose und therapie humaner tumore
MXPA05004677A (es) 2002-10-31 2005-11-17 Genentech Inc Metodos y composiciones para aumentar la produccion de anticuerpos.
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
KR101351122B1 (ko) * 2003-05-09 2014-01-14 듀크 유니버시티 Ｃｄ２０-특이적 항체 및 이를 이용한 방법
US7700097B2 (en) * 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
GB0315457D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
CA2531118C (en) 2003-07-01 2013-01-08 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
PT1644412E (pt) 2003-07-01 2015-12-23 Ucb Biopharma Sprl Fragmentos de anticorpos fab modificados
CA2534898A1 (en) * 2003-08-08 2005-02-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
WO2005021594A2 (en) 2003-08-29 2005-03-10 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use
GB0325836D0 (en) * 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
EP1983000B1 (de) 2003-11-21 2015-09-02 UCB Biopharma SPRL Verfahren zur Behandlung von multipler Sklerose mittels Hemmung der IL-17-Aktivität
GB0329825D0 (en) * 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
AU2005235718B2 (en) 2004-04-23 2011-09-22 Bundesrepublik Deutschland Letztvertreten Durch Das Robert-Koch-Institut Vertreten Durch Seinen Prasidenten Method for the treatment of T cell mediated conditions by depletion of icos-positive cells in vivo
US20100111856A1 (en) * 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
TR201808537T4 (tr) * 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
CA2585891A1 (en) * 2004-10-29 2006-05-11 Medimmune, Inc. Methods of preventing and treating rsv infections and related conditions
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
CN101171034B (zh) 2005-03-03 2014-06-18 免疫医疗公司 人源化l243抗体
US20110123440A1 (en) * 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
USRE47223E1 (en) 2005-06-20 2019-02-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
GB0514779D0 (en) * 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
AU2006272555B2 (en) 2005-07-25 2012-03-08 Aptevo Research And Development Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
WO2007031734A1 (en) * 2005-09-14 2007-03-22 Ucb Pharma S.A. Comb polymers
CA2632628C (en) 2005-12-09 2016-01-19 Ucb Pharma S.A. Antibody molecules having specificity for human il-6
NZ569988A (en) * 2006-02-01 2011-09-30 Cephalon Australia Pty Ltd Domain antibody construct which binds to human TNF-alpha and contains a modified hinge region sequence and a truncated CH1 domain
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
PL2099823T5 (pl) * 2006-12-01 2023-02-20 Seagen Inc. Wariant środków wiążących cel i jego zastosowania
BRPI0809042B1 (pt) 2007-03-22 2021-08-31 Biogen Ma Inc. Proteína de ligação a cd154 isolada, seu uso, e composição
PE20090245A1 (es) 2007-05-08 2009-03-17 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos
EP1997830A1 (de) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
WO2008151319A2 (en) * 2007-06-08 2008-12-11 Dow Global Technologies Inc. Expression of soluble antibody fragment by truncation of ch1 domain
EP2185188B1 (de) 2007-08-22 2014-08-06 Medarex, L.L.C. Ortsspezifische bindung von wirkstoffen oder anderen mitteln an gentechnisch hergestellte antikörper mit c-terminalen erweiterungen
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
BRPI0818780A2 (pt) * 2007-10-19 2015-04-22 Genentech Inc Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos
BRPI0819063A2 (pt) 2007-11-27 2020-08-18 The University Of British Columbia método para tratamento de artrite, anticorpo, hibridoma, antagonista de 14-3-3, usos de um antagonista de 14-3-3, composições farmacêuticas, método para redução da expressão de mmp no sinóvio de um paciente e usos de uma composição farmacêutica
SG186017A1 (en) 2007-11-30 2012-12-28 Kalobios Pharmaceuticals Inc Antibodies to the pcrv antigen of pseudomonas aeruginosa
KR20100107501A (ko) * 2008-01-18 2010-10-05 메디뮨 엘엘씨 부위 특이적 접합을 위한 시스테인 조작 항체
WO2009120905A2 (en) 2008-03-26 2009-10-01 Cellerant Therapeutics, Inc. Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof
NZ603059A (en) 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
AU2010216152B2 (en) 2009-02-17 2015-05-14 Ucb Biopharma Sprl Antibody molecules having specificity for human OX40
GB0904214D0 (en) * 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
RU2595379C2 (ru) 2009-04-16 2016-08-27 АббВай Биотерапеутикс Инк. АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ
RU2567639C2 (ru) 2009-06-17 2015-11-10 АббВай Биотерапеутикс Инк., Антитела против vegf и их применения
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
GB0916630D0 (en) 2009-09-22 2009-11-04 Secr Defence Antibody
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
RS57966B1 (sr) 2009-10-16 2019-01-31 Progastrine Et Cancers S A R L Monoklonska antitela na progastrin i njihova upotreba
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
CN102781963B (zh) 2009-10-27 2018-02-16 Ucb医药有限公司 功能修饰性NAv1.7抗体
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
US8658175B2 (en) 2009-10-28 2014-02-25 Abbvie Biotherapeutics Inc. Anti-EGFR antibodies and their uses
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB0920324D0 (en) 2009-11-19 2010-01-06 Ucb Pharma Sa Antibodies
EP2513148B1 (de) 2009-12-16 2016-08-31 AbbVie Biotherapeutics Inc. Anti-her2-antikörper und ihre verwendung
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
CN102892786B (zh) 2010-03-11 2016-03-16 Ucb医药有限公司 Pd-1抗体
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
WO2011113019A2 (en) 2010-03-12 2011-09-15 Abbott Biotherapeutics Corp. Ctla4 proteins and their uses
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
WO2011117653A1 (en) 2010-03-25 2011-09-29 Ucb Pharma S.A. Disulfide stabilized dvd-lg molecules
CA3220104A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
PH12013501435B1 (en) 2011-01-14 2019-02-01 UCB Biopharma SRL Antibody molecules which bind il-17a and il-17f
BR112014006175B1 (pt) 2011-09-16 2020-02-11 Ucb Pharma S.A. Anticorpos capazes de neutralisar as exotoxinas principais tcda e tcdb de clostridium difficile
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
EP2783214A2 (de) 2011-11-23 2014-10-01 The Board of Regents of The University of Texas System Proteomischer nachweis von antikörpern
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
EA201591465A1 (ru) 2013-02-08 2015-12-30 АйАрЭм ЭлЭлСи Специфичные участки для модификации антител для получения иммуноконъюгатов
AU2014233478A1 (en) 2013-03-15 2015-09-24 Abbvie Biotechnology Ltd. Anti-CD25 antibodies and their uses
EP2970489A2 (de) 2013-03-15 2016-01-20 AbbVie Biotechnology Ltd Anti-cd25-antikörper und deren verwendungen
ES2699599T3 (es) 2013-03-15 2019-02-11 Abbvie Biotherapeutics Inc Variantes de Fc
GB201315487D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
WO2015035044A2 (en) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
JP6397933B2 (ja) 2014-01-20 2018-09-26 ユーシービー バイオファルマ エスピーアールエル 固体形態の医薬組成物の再構成のための方法
MX2016010295A (es) 2014-02-11 2016-10-17 Seattle Genetics Inc Reduccion selectiva de proteinas.
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP2944962A1 (de) 2014-05-14 2015-11-18 UCB Biopharma SPRL Verfahren zur Bestimmung von Antikörperspezifität
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
JP2017531620A (ja) 2014-09-12 2017-10-26 ジェネンテック， インコーポレイテッド システイン操作抗体及びコンジュゲート
WO2016054114A1 (en) 2014-09-29 2016-04-07 The Regents Of The University Of California Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions
JP6805142B2 (ja) 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｄ７３に対する抗体およびその使用
ES2826566T3 (es) 2014-11-21 2021-05-18 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas
JP6807327B2 (ja) 2014-12-22 2021-01-06 ユーシービー バイオファルマ エスアールエル タンパク質製造
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
SG11201706659WA (en) 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
KR20170138570A (ko) 2015-04-30 2017-12-15 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 대사 장애를 치료하기 위한 항-aP2 항체 및 항원 결합 물질
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
JP6851322B2 (ja) 2015-05-27 2021-03-31 ユーシービー バイオファルマ エスアールエル 神経疾患を治療する方法
SG10202010735PA (en) 2015-07-06 2020-11-27 UCB Biopharma SRL Tau-binding antibodies
CN108136012B (zh) * 2015-08-07 2022-10-04 伊麦吉纳博公司 靶向分子的抗原结合构建体
JP6967221B2 (ja) 2015-08-19 2021-11-17 国立研究開発法人理化学研究所 非天然アミノ酸導入抗体
HK1251480A1 (zh) 2015-09-21 2019-02-01 Aptevo Research And Development Llc Cd3结合多肽
CN108350068A (zh) 2015-10-27 2018-07-31 Ucb生物制药私人有限公司 使用抗-il-17a/f抗体的治疗方法
US20180271998A1 (en) 2015-12-04 2018-09-27 Merrimack Pharmaceuticals, Inc. Disulfide-stabilized fabs
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
EP3184544A1 (de) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Glycoprotein-v-inhibitoren zur verwendung als koagulansien
GB201602414D0 (en) 2016-02-10 2016-03-23 Nascient Ltd Biological materials and uses thereof
EA039201B1 (ru) 2016-03-17 2021-12-16 Нумаб Инновейшн Аг Антитела к фно и их функциональные фрагменты
EA039323B1 (ru) 2016-03-17 2022-01-13 Нумаб Инновейшн Аг Антитела к фно и их функциональные фрагменты
EP3219727B1 (de) 2016-03-17 2020-12-16 Tillotts Pharma AG Anti-tnf-alpha-antikörper und funktionale fragmente davon
PT3219726T (pt) 2016-03-17 2020-12-15 Tillotts Pharma Ag Alfa-anticorpos anti-tnf e fragmentos funcionais dos mesmos
IL261793B2 (en) 2016-03-17 2025-04-01 Numab Therapeutics AG ANTI-TNFALPHA ANTIBODIES AND THEIR FUNCTIONAL PARTS
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP3504244A4 (de) 2016-08-26 2020-08-19 Agency for Science, Technology and Research Makrophagenstimulierender proteinrezeptor (oder ron - recepteur d' origine nantais)-antikörper und verwendungen davon
GB201616596D0 (en) 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
SG11201907288RA (en) 2017-02-28 2019-09-27 Seattle Genetics Inc Cysteine mutated antibodies for conjugation
US20200165347A1 (en) 2017-06-30 2020-05-28 Aslan Pharmaceuticals Pte Ltd Method of treatment using il-13r antibody
DK3720879T3 (da) 2017-12-05 2022-06-20 Progastrine Et Cancers S A R L Kombinationsterapi mellem anti-progastrin-antistof og immunterapi til behandling af cancer
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
EP3759492A1 (de) 2018-02-27 2021-01-06 ECS-Progastrin SA Progastrin als biomarker für immuntherapie
AU2019289176B2 (en) 2018-06-18 2026-02-19 Adelaide university Gremlin-1 antagonist for the prevention and treatment of cancer
GB201811368D0 (en) 2018-07-11 2018-08-29 Ucb Biopharma Sprl Antibody
JP7518821B2 (ja) 2018-10-16 2024-07-18 ユーシービー バイオファルマ エスアールエル 重症筋無力症の治療方法
WO2020197502A1 (en) 2019-03-26 2020-10-01 Aslan Pharmaceuticals Pte Ltd Treatment employing anti-il-13r antibody or binding fragment thereof
EP4025606A1 (de) 2019-09-04 2022-07-13 Y-Biologics Inc. Anti-vsig4-antikörper oder antigenbindendes fragment und verwendungen davon
JP7777524B2 (ja) 2019-11-04 2025-11-28 コード バイオセラピューティクス インコーポレイテッド 脳特異的血管新生抑制因子１（ｂａｉ１）抗体及びその使用
GB201919058D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
GB202001447D0 (en) 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
US20240067758A1 (en) 2020-12-07 2024-02-29 UCB Biopharma SRL Multi-specific antibodies and antibody combinations
BR112023008265A2 (pt) 2020-12-07 2024-02-06 UCB Biopharma SRL Anticorpos contra interleucina-22
WO2022186772A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
WO2022186773A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION
WO2022184853A1 (en) 2021-03-03 2022-09-09 Pierre Fabre Medicament Anti-vsig4 antibody or antigen binding fragment and uses thereof
JP2024519415A (ja) 2021-04-30 2024-05-13 ピエール ファーブル メディカモン 新しい安定な抗ｖｉｓｔａ抗体
AR125732A1 (es) 2021-05-03 2023-08-09 UCB Biopharma SRL Anticuerpos anti-trem1
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
JP2024534717A (ja) 2021-09-27 2024-09-24 アスラン ファーマシューティカルズ ピーティーイー リミテッド 中等症から重症のアトピー性皮膚炎の処置のための方法
WO2023048650A1 (en) 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
WO2023075702A1 (en) 2021-10-29 2023-05-04 Aslan Pharmaceuticals Pte Ltd Anti-il-13r antibody formulation
WO2023140780A1 (en) 2022-01-24 2023-07-27 Aslan Pharmaceuticals Pte Ltd. Method of treating inflammatory disease
TW202337905A (zh) 2022-02-23 2023-10-01 新加坡商亞獅康私人有限公司 抗il13r抗體之糖基化形式
KR20250075749A (ko) 2022-08-26 2025-05-28 아슬란 파마슈티컬스 피티이 엘티디 항-il13r 항체의 고농도 제형
CN120077070A (zh) 2022-09-06 2025-05-30 亚狮康私人有限公司 皮炎患者的睡眠缺失或睡眠障碍的治疗
WO2024121380A1 (en) 2022-12-08 2024-06-13 Pierre Fabre Medicament Vaccinal composition and adjuvant
US20260217861A1 (en) 2022-12-22 2026-07-30 Jjulius-Maximilians-Universität-Würzburg Antibodies for use as coagulants
EP4431526A1 (de) 2023-03-16 2024-09-18 Emfret Analytics GmbH & Co. KG Anti-gpvi-antikörper und funktionelle fragmente davon
TW202613165A (zh) 2024-05-17 2026-04-01 比利時商Ｕｃｂ生物製藥公司 具有il-11和il-17結合特異性的多特異性抗體
WO2025238135A2 (en) 2024-05-17 2025-11-20 UCB Biopharma SRL Antibody with binding specificity for il-11
WO2026027660A1 (en) 2024-08-02 2026-02-05 UCB Biopharma SRL Formulations of anti-gremlin-1 antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334102D0 (en) * 1983-12-21 1984-02-01 Searle & Co Interferons with cysteine pattern
JPS6147500A (ja) * 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) * 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DE3689123T2 (de) * 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL84285A (en) * 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product

Also Published As

Publication number Publication date
JP2675380B2 (ja) 1997-11-12
WO1989001974A1 (en) 1989-03-09
DK216089D0 (da) 1989-05-03
DE3877955T2 (de) 1993-07-22
FI892135A7 (fi) 1989-05-03
JP2761012B2 (ja) 1998-06-04
EP0329755A1 (de) 1989-08-30
DK215889A (da) 1989-05-03
ATE102254T1 (de) 1994-03-15
AU617367B2 (en) 1991-11-28
JPH02501191A (ja) 1990-04-26
FI892137L (fi) 1989-05-03
GB8720833D0 (en) 1987-10-14
WO1989001782A1 (en) 1989-03-09
AU2301688A (en) 1989-03-31
AU614303B2 (en) 1991-08-29
JPH02501800A (ja) 1990-06-21
DK216189D0 (da) 1989-05-03
FI892137A7 (fi) 1989-05-03
AU2421888A (en) 1989-03-31
FI892136A0 (fi) 1989-05-03
AU611202B2 (en) 1991-06-06
JPH02501190A (ja) 1990-04-26
DK215889D0 (da) 1989-05-03
WO1989001783A2 (en) 1989-03-09
US5219996A (en) 1993-06-15
WO1989001783A3 (en) 1989-04-20
DK216089A (da) 1989-05-03
CA1337641C (en) 1995-11-28
EP0347433B1 (de) 1994-03-02
DK216189A (da) 1989-05-03
EP0348442B1 (de) 1993-01-27
AU2301388A (en) 1989-03-31
FI892137A0 (fi) 1989-05-03
DE3888172T2 (de) 1994-06-30
FI892136L (fi) 1989-05-03
EP0348442A1 (de) 1990-01-03
EP0347433A1 (de) 1989-12-27
DE3888172D1 (de) 1994-04-07
FI892135L (fi) 1989-05-03
CA1337640C (en) 1995-11-28
DE3877955D1 (de) 1993-03-11
DK172630B1 (da) 1999-03-22
FI892135A0 (fi) 1989-05-03
FI892136A7 (fi) 1989-05-03

Similar Documents

Publication Publication Date Title
ATE102254T1 (de) Rekombinant-antikoerper.
FR2437213A1 (fr) Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
ES2068907T3 (es) Secuencias de nucleotidos que codifican una proteina con actividad ureasica.
ES8306714A1 (es) "procedimiento para la obtencion de un compuesto polipeptidico tiolado".
NO20001668D0 (no) Anvendelse av et DNA-fragment, samt komplementære kjeder, derivater og deler derav
NO895028D0 (no) Ny chimerisk transformerende vekstfaktor-beta.
DE3480494D1 (en) Method and reagent for use in the assay of pivka-ii
PT81528B (pt) Processo para a sintese de peptideos
FI890459A0 (fi) Proteolytisk enzym specifik foer humant immunbristvirus och foerfarande foer dess syntetisering och renaturering.
DE69216600D1 (de) Synthetisches CDw52(CAMPATH-1) Peptidantigen
ATE133993T1 (de) Protein-antikrebsmittel
JPS6461499A (en) Monoclonal antibody to human papilloma viruses 16 type e7 protein, and production and use thereof
EP0287397A3 (en) Monoclonal antibody specific to human pancreatic phospholipase a2
ES2173879T3 (es) Procedimiento para la preparacion de conjugados a base de un participe especifico en la fijacion y de una proteina que contiene hidratos de carbono
ATE58397T1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
AU1062588A (en) Immunoassay utilizing microparticle neutralization
DE59611353D1 (de) Transketolase-verwandtes protein
JPS5386014A (en) Quantitative analysis of antigen and antibody
DE69333364T2 (de) REKOMBINANTES CDw52 ANTIGEN
HUT49151A (en) Process for production of biotinilated proteins

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee